NCT04543188 2025-10-23
A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement
Pfizer
Phase 1 Terminated
Clinical Trials
11 trialsNCT04908176 2024-12-13
A Drug-drug Interaction Study of Avapritinib and Midazolam
Blueprint Medicines Corporation
Phase 1 Completed
NCT03420742 2023-01-27
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors
Takeda
Phase 1 Completed
NCT04727138 2022-05-16
3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
Exscientia AI Limited
Phase 1 Completed
NCT02244112 2021-02-21
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
Amgen
Phase 1 Terminated
NCT02686164 2019-08-28
Phase 1 Study to Determine the Effect of Lenvatinib (E7080) on the Pharmacokinetics of Midazolam in Subjects With Advanced Solid Tumors
Eisai Inc.
Phase 1 Completed
NCT01287598 2019-07-10
BAY73-4506 Probe Substrate Study
Bayer
Phase 1 Completed
NCT01517399 2019-02-12
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
Daiichi Sankyo
Phase 1 Completed
NCT00880321 2017-11-13
A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors
GlaxoSmithKline
Phase 1 Completed
NCT02082665 2017-07-24
Effects of Dabrafenib on the Single Dose Pharmacokinetics (PK) of Rosuvastatin and Midazolam
GlaxoSmithKline
Phase 1 Completed
NCT01026415 2014-12-18
Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)
Seagen Inc.
Phase 1 Completed